The article provides an overview of analyst ratings for Arrowhead Pharma, showing a mix of bullish and indifferent ratings. The average 12-month price target has increased by 26.54% from the previous average, indicating a potential upside. However, the mixed ratings suggest uncertainty in the short term, leading to a neutral score.